Salts
    3.
    发明授权
    Salts 有权

    公开(公告)号:US08697682B2

    公开(公告)日:2014-04-15

    申请号:US13856371

    申请日:2013-04-03

    IPC分类号: A61K31/397 C07D205/04

    CPC分类号: A61K31/397 C07D205/04

    摘要: This invention relates to a hydrochloride, malate, oxalate and tartrate salt forms of 1-(4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl}-2-ethyl-benzyl)-azetidine-3-carboxylic acid (Compound I), to pharmaceutical compositions comprising this salt, to processes for forming this salt and to its use in medical treatment. In addition, the present invention also relates to new polymorphic forms of each of these salts, as well as to pharmaceutical compositions comprising these polymorphic forms, to processes for obtaining them, and their use in medical treatment.

    摘要翻译: 本发明涉及1-(4- {1 - [(E)-4-环己基-3-三氟甲基 - 苄氧基亚氨基] - 乙基} -2-乙基 - 苄基) - 氮杂环丁烷的盐酸盐,苹果酸盐,草酸盐和酒石酸盐 -3-羧酸(化合物I),包含该盐的药物组合物,用于形成该盐的方法及其在医疗中的用途。 此外,本发明还涉及这些盐中的每一种的新的多晶形式,以及包含这些多晶型形式的药物组合物,获得它们的方法及其在医疗中的用途。

    Microprecipitation of nanoparticulate pharmaceutical agents
    4.
    发明授权
    Microprecipitation of nanoparticulate pharmaceutical agents 失效
    纳米颗粒药剂的微沉淀

    公开(公告)号:US5560932A

    公开(公告)日:1996-10-01

    申请号:US370955

    申请日:1995-01-10

    IPC分类号: A61K9/14 A61K49/04

    摘要: This invention describes the preparation of nanoparticulate pharmaceutical agent dispersion via a process that comprises the dissolution of the said pharmaceutical agent in an alkaline solution and then neutralizing the said solution with an acid in the presence of a suitable surface-modifying, surface-active agent to form a fine particle dispersion of the said pharmaceutical agent. This can be preferably followed by steps of diafiltration clean-up of the dispersion and then concentration of it to a desired level. This process of dispersion preparation leads to microcrystalline particles of Z-average diameters smaller than 400 nm as measured by photon correlation spectroscopy. Various modification of precipitation schemes are described, many of which are suitable for large-scale manufacture of these agent dispersions.

    摘要翻译: 本发明描述了通过包括将所述药剂溶解在碱性溶液中然后在合适的表面改性表面活性剂存在下用酸中和所述溶液的方法制备纳米颗粒药剂分散体, 形成所述药剂的细颗粒分散体。 这可以优选地随后是分散体的渗滤清洗步骤,然后将其浓缩到期望的水平。 这种分散制备过程导致通过光子相关光谱测量的Z平均直径小于400nm的微晶颗粒。 描述了各种改性的沉淀方案,其中许多适用于这些试剂分散体的大规模制造。

    NEW SALTS
    5.
    发明申请
    NEW SALTS 有权
    新销售

    公开(公告)号:US20110257150A1

    公开(公告)日:2011-10-20

    申请号:US13140490

    申请日:2009-12-17

    CPC分类号: A61K31/397 C07D205/04

    摘要: This invention relates to a hydrochloride, malate, oxalate and tartrate salt forms of 1-(4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl}-2-ethyl-benzyl)-azetidine-3-carboxylic acid (Compound I), to pharmaceutical compositions comprising this salt, to processes for forming this salt and to its use in medical treatment. In addition, the present invention also relates to new polymorphic forms of each of these salts, as well as to pharmaceutical compositions comprising these polymorphic forms, to processes for obtaining them, and their use in medical treatment.

    摘要翻译: 本发明涉及1-(4- {1 - [(E)-4-环己基-3-三氟甲基 - 苄氧基亚氨基] - 乙基} -2-乙基 - 苄基) - 氮杂环丁烷的盐酸盐,苹果酸盐,草酸盐和酒石酸盐 -3-羧酸(化合物I),包含该盐的药物组合物,用于形成该盐的方法及其在医疗中的用途。 此外,本发明还涉及这些盐中的每一种的新的多晶形式,以及包含这些多晶型形式的药物组合物,获得它们的方法及其在医疗中的用途。